Cited by 498Cannabis and Cannabinoid ResearchAdenosine and Purinergic SignalingInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression

Open access

Carrier, Erica J., Auchampach, John A., Hillard, Cecilia J.·2006·Proceedings of the National Academy of Sciences

Open this paper in CoChat — free account Open PDF

Abstract

The plant-derived cannabinoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both have immunosuppressive effects; although some effects of THC are mediated by the CB2 receptor, CB2 binds CBD weakly. In examining the effects of THC and CBD on microglial proliferation, we found that these compounds potently inhibit [3H]thymidine incorporation into a murine microglial cell line with no effect on cell cycle. Treatment with THC and CBD decreased [3H]thymidine uptake into microglia, with IC50 values that match inhibition of [3H]thymidine incorporation into DNA. CBD and, less potently, THC decreased uptake of [3H]adenosine to a similar extent as [3H]thymidine in both murine microglia and RAW264.7 macrophages. Binding studies confirm that CBD binds to the equilibrative nucleoside transporter 1 with a Ki < 250 nM. Because adenosine agonists have antiinflammatory effects, and because uptake of adenosine is a primary mechanism of terminating adenosine signaling, we tested the hypothesis that CBD is immunosuppressive because it enhances endogenous adenosine signaling. In vivo treatment with a low dose of CBD decreases TNFalpha production in lipopolysaccharide-treated mice; this effect is reversed with an A2A adenosine receptor antagonist and abolished in A2A receptor knockout mice. These studies demonstrate that CBD has the ability to enhance adenosine signaling through inhibition of uptake and provide a non-cannabinoid receptor mechanism by which CBD can decrease inflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.0511232103

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Reactive microgliosis
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 900
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R. J., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 570
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T. I., Zimmer, A. M., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 546
The cannabinoid system and immune modulation
Klein, T., Newton, C. A., Larsen, K. A., Lu, L. D., Perkins, I., Nong, L., & Friedman, H. P. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 533
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 530

Show all 39 references

Research works printed but not linked: 7

R. K. Razdan Pharmacol. Rev 38, 75–149 (1986).
R. G. Pertwee Cannabinoids, ed V. Di Marzo (Kluwer Academic/Plenum Publishers, New York), pp. 32–83 (2004).
A. C. Howlett, J. M. Qualy, L. L. Khachatrian Mol. Pharmacol 29, 307–313 (1986).
B. Desoize, C. Leger, J. C. Jardillier, G. Nahas Adv. Biosci 22–23, 145–159 (1978).
B. Desoize, C. Leger, G. Nahas C. R. Hebd. Seances Acad. Sci. D 287, 1441–1444 (1978).
P. G. Smith, H. D. Thomas, H. C. Barlow, R. J. Griffin, B. T. Golding, H. Calvert, D. R. Newell, N. J. Curtin Clin. Cancer Res 7, 2105–2113 (2001).
A. S. Gordon, L. Nagy, D. Mochly-Rosen, I. Diamond Biochem. Soc. Symp 56, 117–136 (1990).

Sorted by citations

Items 101–200 of 498

Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors
Soares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112
Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity
Rosenberg, E. C., Chamberland, S., Bazelot, M., Nebet, E. R., Wang, X., McKenzie, S., Jain, S. S., Greenhill, S., Wilson, M. A., Marley, N., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.01.018 · Cited by 114
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation
Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., & Berry, E. M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.021 · Cited by 111
Cannabinoids and the Brain
Köfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 110
ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids
Shah, S., Schwenk, E. S., Sondekoppam, R. V., Clarke, H. A., Zakowski, M. I., Lynn, R. R., Yeung, B., Nicholson, K., Schwartz, G. S., Hooten, W. M., et al. (2023) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2022-104013 · Cited by 113
The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration
Gowran, A., Noonan, J., & Campbell, V. A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00195.x · Cited by 109
Endocannabinoids: A unique opportunity to develop multitarget analgesics
Maione, S., Costa, B., & Marzo, V. D. (2013) · Pain · doi:10.1016/j.pain.2013.03.023 · Cited by 104
The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids
Cheung, K. A. K., Peiris, H. N., Wallace, G., Holland, O. J., & Mitchell, M. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236079 · Cited by 105
Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism
Hayakawa, K., Mishima, K., Irie, K., Hazekawa, M., Mishima, S., Fujioka, M., Orito, K., Egashira, N., Katsurabayashi, S., Takasaki, K., et al. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.040 · Cited by 105
The Effect of Cannabidiol on Ischemia/Reperfusion-Induced Ventricular Arrhythmias
Gonca, E., & Darıcı, F. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414532013 · Cited by 106
ATP and adenosine—Two players in the control of seizures and epilepsy development
Beamer, E. H., Kuchukulla, M., Boison, D., & Engel, T. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102105 · Cited by 103
Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials
de Bitencourt, R. M., & Takahashi, R. N. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00502 · Cited by 108
Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT 1A receptors
Gomes, F. V., Reis, D. G., Alves, F. H., Corrêa, F. M., Guimarães, F. S., & Resstel, L. B. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881110389095 · Cited by 97
The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation
Maayah, Z. H., Takahara, S., Ferdaoussi, M., & Dyck, J. R. B. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165771 · Cited by 103
Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum
Pandolfo, P., Silveirinha, V., dos Santos‐Rodrigues, A., Venance, L., Ledent, C. A., Takahashi, R. N., Cunha, R. A., & Köfalvi, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.013 · Cited by 96
Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation
Camilleri, M., Carlson, P., McKinzie, S., Grudell, A., Busciglio, I. A., Burton, D. D., Baxter, K. L., Ryks, M. D., & Zinsmeister, A. R. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00371.2007 · Cited by 95
Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs
Lafuente, H., Alvarez, F. J., Pazos, M. R., Alvarez, A. A., Rey-Santano, M. C., Mielgo, V., Murgia-Esteve, X., Hilario, E., & Martínez-Orgado, J. A. (2011) · Pediatric Research · doi:10.1203/pdr.0b013e3182276b11 · Cited by 94
Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms
Silote, G. P., Sartim, A. G., Sales, A. J., Eskelund, A., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2019.04.006 · Cited by 98
Cannabidiol improves brain and liver function in a fulminant hepatic failure‐induced model of hepatic encephalopathy in mice
Avraham, Y., Grigoriadis, N. K., Poutahidis, T., Vorobiev, L., Magen, I., Ilan, Y., Mechoulam, R., & Berry, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01179.x · Cited by 93
Anxiogenic-like effects of chronic cannabidiol administration in rats
ElBatsh, M. M., Assareh, N., Marsden, C. A., & Kendall, D. A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2566-z · Cited by 96
Endocannabinoids: A Promising Impact for Traumatic Brain Injury
Schurman, L. D., & Lichtman, A. H. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00069 · Cited by 95
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
Silvestro, S., Schepici, G., Bramanti, P., & Mazzon, E. (2020) · Molecules · doi:10.3390/molecules25215186 · Cited by 93
Cannabidiol does not display drug abuse potential in mice behavior
Viudez‐Martínez, A., García‐Gutiérrez, M. S., Medrano-Relinque, J., Navarrón, C. M., Navarrete, F., & Manzanares, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0032-8 · Cited by 92
Repeated treatment with cannabidiol but not Δ9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance
Hayakawa, K., Mishima, K., Nozako, M., Ogata, A., Hazekawa, M., Liu, A.-X., Fujioka, M., Abe, K., Hasebe, N., Egashira, N., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.005 · Cited by 89
Cannabinoid interactions with ion channels and receptors
Watkins, A. R. (2019) · Channels · doi:10.1080/19336950.2019.1615824 · Cited by 91
Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases
Chang, C., Wu, K.-C., Lin, C., & Chern, Y. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00766-y · Cited by 90
The Pharmacology and Therapeutic Potential of Plant Cannabinoids
Cascio, M. G., Pertwee, R. G., & Marini, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-54564-6_9 · Cited by 94
Latest advances in cannabinoid receptor agonists
Thakur, G. A., Tichkule, R. B., Bajaj, S., & Makriyannis, A. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903436505 · Cited by 87
Neuropathic pain, mood, and stress-related disorders: A literature review of comorbidity and co-pathogenesis
Vieira, W. F., Coelho, D. R. A., Litwiler, S. T., McEachern, K. M., Clancy, J. A., Morales-Quezada, L., & Cassano, P. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105673 · Cited by 90
A molecular basis for the anti‐inflammatory and anti‐fibrosis properties of cannabidiol
Sunda, F., & Arowolo, A. (2020) · The FASEB Journal · doi:10.1096/fj.202000975r · Cited by 91
Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor‐independent myeloperoxidase‐inhibiting mechanism
Hayakawa, K., Mishima, K., Nozako, M., Hazekawa, M., Irie, K., Fujioka, M., Orito, K., Abe, K., Hasebe, N., Egashira, N., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04565.x · Cited by 84
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects
Hallak, J. E. C., Dursun, S. M., Bosi, D. C., de Macedo, L. R. H., Machado-de-Sousa, J. P., Abrão, J., Crippa, J. A. S., McGuire, P., Krystal, J. H., Baker, G. B., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.002 · Cited by 83
Statement on safety of cannabidiol as a novel food: data gaps and uncertainties
EFSA Panel on Nutrition, N. F. A. F. A. (., Turck, D., Bohn, T., Castenmiller, J. J. M., Henauw, S. D., Hirsch‐Ernst, K. I., Maciuk, A., Mangelsdorf, I., McArdle, H. J., Naska, A., et al. (2022) · EFSA Journal · doi:10.2903/j.efsa.2022.7322 · Cited by 88
Cannabis and Endocannabinoid Signaling in Epilepsy
Katona, I. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_10 · Cited by 86
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
Zlebnik, N. E., & Cheer, J. F. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014038 · Cited by 82
The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease
Karl, T., Garner, B., & Cheng, D. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000247 · Cited by 83
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
Navarrete, F., García‐Gutiérrez, M. S., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.626010 · Cited by 81
Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action
Anil, S. M., Peeri, H., & Koltai, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.908198 · Cited by 76
The Future of Cannabinoids as Analgesic Agents: A Pharmacologic, Pharmacokinetic, and Pharmacodynamic Overview
McCarberg, B. H., & Barkin, R. L. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180a5e581 · Cited by 76
Cannabinoid interventions for PTSD: Where to next?
Ney, L. J., Matthews, A. J., Bruno, R., & Felmingham, K. L. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.03.017 · Cited by 77
Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors
Espejo‐Porras, F., Fernández‐Ruíz, J., Pertwee, R. G., Mechoulam, R., & García, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.024 · Cited by 75
The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne
Peyravian, N., Deo, S. K., Daunert, S., & Jimenez, J. J. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s355489 · Cited by 74
Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice
Gomes, F. V., Bel, E. A. D., & Guimarães, F. S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.005 · Cited by 77
“Redundancy” of Endocannabinoid Inactivation: New Challenges and Opportunities for Pain Control
Piscitelli, F., & Marzo, V. D. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300015x · Cited by 75
Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury
Belardo, C., Iannotta, M., Boccella, S., Rubino, R. C., Ricciardi, F., Infantino, R., Pieretti, G., Stella, L., Paino, S., Marabese, I., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00352 · Cited by 73
Cannabidiol as a Novel Therapeutic for Immune Modulation
Peyravian, N., Deo, S. K., Daunert, S., & Jimenez, J. J. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s263690 · Cited by 79
Pharmacological effects of cannabidiol by transient receptor potential channels
Etemad, L., Karimi, G., Alavi, M. S., & Roohbakhsh, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120582 · Cited by 73
An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects
Naya, N. M., Kelly, J., Corna, G., Golino, M., Polizio, A. H., Abbate, A., Toldo, S. A., & Mezzaroma, E. (2024) · Molecules · doi:10.3390/molecules29020473 · Cited by 83
Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases
Rapino, C., Tortolani, D., Scipioni, L., & Maccarrone, M. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170724104305 · Cited by 73
Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease
Hughes, B., & Herron, C. E. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2513-z · Cited by 77
Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation.
El‐Remessy, A. B., Tang, Y., Zhu, G., Matragoon, S., Khalifa, Y., Liu, E. K., Liu, J.-Y., Hanson, E. M., Mian, S. I., Fatteh, N., et al. (2008) · PubMed Central · Cited by 70
Retracted
The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice
Shirazi-zand, Z., Ahmad-Molaei, L., Motamedi, F., & Naderi, N. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.03.009 · Cited by 70
The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice
Li, H., Kong, W., Chambers, C. R., Yu, D., Ganea, D., Tuma, R. F., & Ward, S. J. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.016 · Cited by 69
Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: Contribution of 5HT1A receptors and stressful experiences
Marinho, A. L. Z., Vila-Verde, C., Fogaça, M. V., & Guimarães, F. S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.02.023 · Cited by 68
Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research
Franco, V., Bialer, M., & Perucca, E. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108442 · Cited by 70
The N ‐Acylethanolamine‐Mediated Regulatory Pathway in Plants
Kilaru, A., Blancaflor, E. B., Venables, B. J., Tripathy, S., Mysore, K. S., & Chapman, K. D. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790161 · Cited by 68
Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
Hayakawa, K., Mishima, K., & Fujiwara, M. (2010) · Pharmaceuticals · doi:10.3390/ph3072197 · Cited by 73
Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats
Campos, A. C., de Paula Soares, V., Carvalho, M. C., Ferreira, F. R., Vicente, M. A., Brandão, M. L., Zuardi, A. W., Zangrossi, H., & Guimarães, F. S. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2878-7 · Cited by 65
Neuroprotective and Intraocular Pressure-Lowering Effects of (–)Δ9-Tetrahydrocannabinol in a Rat Model of Glaucoma
Crandall, J., Matragoon, S., Khalifa, Y. M., Borlongan, C., Tsai, N., Caldwell, R. B., & Liou, G. I. (2007) · Ophthalmic Research · doi:10.1159/000099240 · Cited by 64
Decoding the Postulated Entourage Effect of Medicinal Cannabis: What It Is and What It Isn’t
Christensen, C., Rose, M., Cornett, C., & Allesø, M. (2023) · Biomedicines · doi:10.3390/biomedicines11082323 · Cited by 75
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
Tayo, B., Taylor, L., Sahebkar, F., & Morrison, G. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00841-6 · Cited by 66
The Neurotherapeutic Arsenal in Cannabis sativa: Insights into Anti-Neuroinflammatory and Neuroprotective Activity and Potential Entourage Effects
Al-Khazaleh, A. K., Zhou, X., Bhuyan, D. J., Münch, G. W., Al-Dalabeeh, E. A., Jaye, K. M., & Chang, D. (2024) · Molecules · doi:10.3390/molecules29020410 · Cited by 66
Role of Cannabinoids in Pain Management
Russo, E. B., & Hohmann, A. G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1560-2_18 · Cited by 62
Cannabidiol post-treatment alleviates rat epileptic-related behaviors and activates hippocampal cell autophagy pathway along with antioxidant defense in chronic phase of pilocarpine-induced seizure
Hosseinzadeh, M., Nikseresht, S., Khodagholi, F., Naderi, N., & Maghsoudi, N. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0703-6 · Cited by 61
Cannabidiol and brain function: current knowledge and future perspectives
Schouten, M., Dalle, S., Mantini, D., & Koppo, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1328885 · Cited by 64
Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice
Jan, T., Su, S.-T., Wu, H., & Liao, M.-H. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.01.015 · Cited by 61
Perioperative Pain and Addiction Interdisciplinary Network (PAIN): consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users by a modified Delphi process
Ladha, K. S., McLaren-Blades, A., Goel, A., Buys, M. J., Farquhar-Smith, P. W., Haroutounian, S., Kotteeswaran, Y., Kwofie, K., Foll, B. L., Lightfoot, N. J., et al. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.09.026 · Cited by 62
Endocannabinoid System and Its Regulation by Polyunsaturated Fatty Acids and Full Spectrum Hemp Oils
Komarnytsky, S., Thirumurugan, R., Wagner, C., Metzger, B. T., Carlisle, C., Panda, C., Brun-Blashka, S. L., TROUP, J. P., & Varadharaj, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115479 · Cited by 58
Cannabidiol goes nuclear: The role of PPARγ
Khosropoor, S., Alavi, M. S., Etemad, L., & Roohbakhsh, A. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154771 · Cited by 58
The effects of cannabidiol on male reproductive system: A literature review
de Carvalho, R. K., Andersen, M. L., & Mazaro‐Costa, R. (2019) · Journal of Applied Toxicology · doi:10.1002/jat.3831 · Cited by 58
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation
Gyires, K., & Zádori, Z. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160303110150 · Cited by 59
Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus: Cannabidiol Blunts Δ9-Tetrahydrocannabinol-Induced Cognitive Impairment
Aso, E., Fernández-Dueñas, V., López-Cano, M., Taura, J., Watanabe, M., Ferrer, I., Luján, R., & Ciruela, F. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1456-3 · Cited by 46
The role of 5-HT 1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae)
Twardowschy, A., Castiblanco-Urbina, M. A., Uribe-Mariño, A., Biagioni, A. F., Salgado-Rohner, C. J., Crippa, J. A. S., & Coimbra, N. C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113493363 · Cited by 56
R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: Partial involvement of the CB2 receptor
Sánchez, A., González-Pérez, P., Galve‐Roperh, I., & García‐Merino, A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.018 · Cited by 56
The Impact of Feeding Cannabidiol (CBD) Containing Treats on Canine Response to a Noise-Induced Fear Response Test
Morris, E. M., Kitts-Morgan, S. E., Spangler, D. M., McLeod, K. R., Costa, J. H. C., & Harmon, D. L. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.569565 · Cited by 55
Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples
Gidal, B. E., Vandrey, R. G., Wallin, C. M., Callan, S. P., Sutton, A., Saurer, T. B., & Triemstra, J. L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1335441 · Cited by 55
Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress
Granjeiro, É. M., Gomes, F. V., Guimarães, F. S., Corrêa, F. M. D. A., & Resstel, L. B. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.027 · Cited by 57
Cannabinoids as hippocampal network administrators
Lupica, C. R., Hu, Y., Devinsky, O., & Hoffman, A. F. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.003 · Cited by 55
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
Gunning, B. W., Mazurkiewicz‐Bełdzińska, M., Chin, R., Bhathal, H., Nortvedt, C., Dunayevich, E., & Checketts, D. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13351 · Cited by 54
Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice
Karmaus, P. W. F., Wagner, J. G., Harkema, J. R., Kaminski, N. E., & Kaplan, B. L. F. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.741628 · Cited by 54
Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats
Genaro, K., Fabris, D., Arantes, A. L. F., Zuardi, A. W., Crippa, J. A. S., & Prado, W. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00391 · Cited by 55
Clinical studies and anti‐inflammatory mechanisms of treatments
French, J. A., Koepp, M. J., Naegelin, Y., Vigevano, F., Auvin, S., Rho, J. M., Rosenberg, E. C., Devinsky, O., Olofsson, P. S., & Dichter, M. A. (2017) · Epilepsia · doi:10.1111/epi.13779 · Cited by 54
Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids
Martinelli, G., Magnavacca, A., Fumagalli, M., Dell’Agli, M., Piazza, S., & Sangiovanni, E. (2021) · Planta Medica · doi:10.1055/a-1420-5780 · Cited by 55
Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells
Giudice, E. D., Rinaldi, L., Passarotto, M., Facchinetti, F., D’Arrigo, A., Guiotto, A., Carbonare, M. D., Battistin, L., & Leon, A. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1206738 · Cited by 54
The Pharmacological History of Cannabis
Russo, E. B. (2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.003.0002 · Cited by 53
Manipulation of the Endocannabinoid System in Colitis
Leinwand, K. L., Gerich, M. E., Hoffenberg, E. J., & Collins, C. B. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001004 · Cited by 53
Cannabidiol selectively modulates interleukin (IL)-1β and IL-6 production in toll-like receptor activated human peripheral blood monocytes
Sermet, S., Li, J., Bach, A. P., Crawford, R. B., & Kaminski, N. E. (2021) · Toxicology · doi:10.1016/j.tox.2021.153016 · Cited by 52
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi, J. F. C., Ferreira, F. R., Silva-Amaral, D., Lima, D. D. A., Hallak, J. E. C., Zuardi, A. W., Bel, E. A. D., Guimarães, F. S., Costa, K. C. M., Campos, A. C., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06196-4 · Cited by 53
Medical use of cannabis. Cannabidiol: A new light for schizophrenia?
Deiana, S. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1425 · Cited by 54
Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative
da Silva, N. R., Gomes, F. V., Fonseca, M. M., Mechoulam, R., Breuer, A., Cunha, T. M., & Guimarães, F. S. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.012 · Cited by 52
Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms
Soderstrom, K., Soliman, E., & Dross, R. V. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00720 · Cited by 52
Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain
de Ternay, J., Naassïla, M., Nourredine, M., Louvet, A., Bailly, F., Sescousse, G., Maurage, P., Cottencin, O., Carrieri, P., & Rolland, B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00627 · Cited by 52
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia
Ferreira‐Junior, N. C., Pereira, M. D. S., Guimarães, F. S., & Bel, E. D. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00109-8 · Cited by 53
Toward a Molecular Basis of Cellular Nucleoside Transport in Humans
Wright, N. A., & Lee, S. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00644 · Cited by 51
Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries
Aychman, M. M., Goldman, D. L., & Kaplan, J. S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1087011 · Cited by 52
Adenosine contribution to normal renal physiology and chronic kidney disease
Oyarzun, C. E., Garrido, W., Alarcón, S., Yáñez, A. J., Sobrevía, L., Quezada, C., & Martín, R. S. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.004 · Cited by 49
Dipyridamole augments the antiinflammatory response during human endotoxemia
Ramakers, B. P., Riksen, N. P., Stal, T. H., Heemskerk, S., van den Broek, P., Peters, W. H. M., van der Hoeven, J. G., Smits, P., & Pickkers, P. (2011) · Critical Care · doi:10.1186/cc10576 · Cited by 48
Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease
Leinwand, K. L., Jones, A., Huang, R. H., Jedlicka, P., Kao, D. J., de Zoeten, E. F., Ghosh, S., Moaddel, R., Wehkamp, J., Ostaff, M. J., et al. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx096 · Cited by 48
Role of the Endocannabinoid System in Depression: from Preclinical to Clinical Evidence
Micale, V., Tabiová, K., Kučerová, J., & Drago, F. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2294-9_5 · Cited by 47
Evidences for the Anti-panic Actions of Cannabidiol
Soares-Rachetti, V. D. P., & Campos, A. C. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160509123955 · Cited by 52

Authors: Carrier, E. J., Auchampach, J. A., & Hillard, C. J.
Affiliations: Medical College of Wisconsin (US)
ORCID: Carrier, Erica J.
Auchampach, John A.
Hillard, Cecilia J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2006-05-16
Volume: 103
Issue: 20
Pages: 7895-7900
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0511232103
OpenAlex: W2067960394
Cited by: 497
References: 39
Citations by year: 2026: 20 · 2025: 30 · 2024: 29 · 2023: 33 · 2022: 40 · 2021: 33 · 2020: 40 · 2019: 32 · 2018: 19 · 2017: 25 · 2016: 20 · 2015: 19 · 2014: 11 · 2013: 20 · 2012: 24
FWCI: 14.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Heart, Lung, and Blood Institute (HL 077707, R01HL077707)
National Institute on Drug Abuse (R01DA009155, DA 16967, DA09155, R01DA016967)
National Institute of Neurological Disorders and Stroke (NS041314, R01NS041314)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords: cannabidiol, delta-9-tetrahydrocannabinol, equilibrative nucleoside transporter 1, adenosine uptake, adenosine signaling, adenosine A2A receptor, microglial proliferation, macrophages, TNF-α, lipopolysaccharide-induced inflammation, anti-inflammatory activity
MeSH terms: Rimonabant, Adenosine, Animals, Camphanes, Cannabidiol, Cell Line, DNA, Immunosuppression Therapy, Lipopolysaccharides, Male, Mice, Inbred C57BL, Piperidines, Psychotropic Drugs, Pyrazoles, Dronabinol, Thymidine, Tumor Necrosis Factor-alpha, Microglia, Nucleoside Transport Proteins, Equilibrative Nucleoside Transporter 1, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks